Researchers at Indiana University School of Medicine are testing use of tezampanel, a novel antagonist at glutamate receptors that could treat opioid withdrawal syndrome and other addictions and mental illnesses.
As researchers around the world work feverishly to discover a vaccine in the battle to prevent COVID-19, Indiana University School of Medicine has been selected as a site for a vaccine trial. Biopharmaceutical company AstraZeneca, in partnership with Oxford University, is moving forward with its late-stage clinical trial for a vaccine known as AZD1222.
In honor of Indiana University’s bicentennial, IU School of Medicine is awarding 11 highly accomplished students with four-year scholarships and inclusion in a leadership development program involving the school’s top executives and esteemed faculty.
INDIANAPOLIS -- A researcher at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center has been awarded a five-year, $5.7 million National Cancer Institute grant to evaluate long-term health outcomes for cancer patients who receive platinum-based chemotherapies. An internationally recognized expert on cancer survivorship, Lois B. Travis, MD, ScD, leads the ongoing study that could lessen cancer treatment side effects for millions of patients.
A veteran researcher and Indiana University School of Medicine faculty member will be taking on a new role with the Indiana Biosciences Research Institute—a leading industry-inspired applied research institute. Alan Palkowitz, PhD, was named the new president and CEO of the IBRI in an announcement on Wednesday, September 2. Palkowitz will spend 80 percent of his time at the IBRI serving in this new position, while maintaining his role at IU School of Medicine as a senior research professor of medicine and leader of the IUSM-Purdue TaRget Enablement to Accelerate Therapy Development for Alzheimer’s Disease (TREAT-AD) Center.
A study conducted by Indiana University School of Medicine researchers has shown that asymptomatic COVID-19 infection is possible in children younger than 10 years old. The researchers have shared the results of their novel COVID-19 study of asymptomatic children and adults in Marion County known as TACTIC (Tracking Asymptomatic COVID-19 Through Indianapolis Communities).
Indiana University School of Medicine is leading the first study of the national Diabetic Foot Consortium with the goal of preventing reopening of closed wounds by identifying a biomarker that would predict such recurrence during the process of standard wound care.
Indiana University School of Medicine has picked an internationally recognized geneticist with more than two decades of experience with the institution to lead its $360 million research enterprise. Tatiana Foroud, PhD has been named the new Executive Associate Dean for Research Affairs and IU Health’s Executive Vice President of Academic Affairs for Clinical Research, effective August 1, 2020.